Skip to main content
Atrás
Watch Compare

ACRO BIOMEDICAL CO., LTD.

Calidad de datos: 100%
ACBM
OTC Services Amusement & Recreation
$0.03
$0.00 (0.00%)
Cap. Mercado: 1.56 M
Precio
$0.03
Cap. Mercado
1.56 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -196,302.0

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio0.01
Interest CoverageN/A

Valoración

PE (TTM)
-15.43
Below sector avg (-1.17)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Services (502 pares)
Métrica Acción Mediana del Sector
P/E -15.4 -1.2
P/B — 1.4
ROE % — -16.0
Net Margin % — -19.4
Rev Growth 5Y % — 4.0
D/E — 0.4

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

No hay estimaciones futuras disponibles

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -101,146.0
ROE N/A ROA -351.20%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -196,302.0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.01
Interest Coverage N/A Asset Turnover 0.00
Working Capital -432,619 Tangible Book Value -432,619
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -15.43 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -12.57%
Market Cap 1.56 M Enterprise Value 1.56 M
Per Share
EPS (Diluted TTM) 0.00 Revenue / Share 0.00
FCF / Share 0.00 OCF / Share 0.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 194.08%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 658,500.0 —
Net Income -101,146.0 -42,297.0 -8.81 M -15.87 M -7.70 M
EPS (Diluted) 0.00 0.00 -0.15 — —
Gross Profit — — 0.0 140,500.0 259,500.0
Operating Income -154,024.0 -37,958.0 -8.80 M -15.87 M -7.69 M
EBITDA — — — — —
R&D Expenses — 0.0 4.79 M 10.08 M —
SG&A Expenses 154,024.0 37,958.0 3.52 M 5.93 M 2.67 M
D&A — — — — —
Interest Expense — — 3,206.0 358.0 893.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,098.0 31,974.0 58,459.0 687,486.0 761,077.0
Total Liabilities — 326,946.0 315,473.0 201,116.0 117,370.0
Shareholders' Equity -386,964.0 -294,972.0 -257,014.0 486,370.0 643,707.0
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 14,098.0 5,076.0 1,626.0 657,537.0 706,415.0
Current Liabilities 401,062.0 326,946.0 288,575.0 201,116.0 91,651.0